SAB Biotherapeutics (SABS) Earnings Analysis
SAB Biotherapeutics (SABS) next reports earnings on 2026-08-06, consensus EPS -0.29 USD. Last quarter (2026-03-09) it missed with EPS -0.46 USD vs -0.16 USD est (-187.5%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E 8.33.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SABS next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.29 USD |
| Revenue estimate | 0.00B |
SABS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-09 | -0.46 USD | -0.16 USD | -187.5% | Miss |
| 2025-11-14 | -0.21 USD | -0.59 USD | +64.4% | Beat |
| 2025-05-09 | -0.56 USD | -1 USD | +44% | Beat |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
SABS valuation and analyst view
| Trailing P/E | 8.33 |
|---|---|
| Trailing EPS | -0.00744 USD |
| Price / book | 0.84 |
| Dividend yield | 0.00% |
| Market cap | 0.03B |
| Analyst consensus | Buy (7 buy / 1 hold / 0 sell) |
| Avg price target | 11.33 USD |
Related research pages
Frequently asked questions
When is SAB Biotherapeutics (SABS)'s next earnings date?
SAB Biotherapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.29 USD and revenue estimate of 0.00B.
Did SABS beat earnings last quarter?
In its 2026-03-09 report, SABS posted EPS of -0.46 USD versus a -0.16 USD estimate — a miss of 187.5%.
What is SABS's earnings track record?
Over the last 3 reported quarters with consensus data, SABS beat estimates 2 times (67%).
What is SABS's current P/E ratio and EPS?
SABS trades at a trailing P/E of 8.33 on trailing EPS of -0.007439117338287853 USD.
What do analysts rate SABS?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 11.33 USD.